Fig. 5: Feasibility of further decreasing the sample volume in the PAβ V2.0 IS assay from 250 μl to 100 μl (n = 49 biological replicates). | Nature Communications

Fig. 5: Feasibility of further decreasing the sample volume in the PAβ V2.0 IS assay from 250 μl to 100 μl (n = 49 biological replicates).

From: Streamlined resource-efficient plasma amyloid-beta mass spectrometry assay has improved biomarker performance in preclinical Alzheimer’s disease

Fig. 5: Feasibility of further decreasing the sample volume in the PAβ V2.0 IS assay from 250 μl to 100 μl (n = 49 biological replicates).

This experiment was performed in a sub-cohort of the IGNITE study selected to reflect balanced demographics. A Box-and-whisker plots for the PAβ V2.0 IS assay using a 100 μl sample volume, and 250 μl sample volume, split into Aβ PET-positive and PET-negative groups, analyzing the Aβ1-42/Aβ1-40 biomarker. Differences were evaluated using the two-sided Wilcoxon Rank Sum test, with p-values provided. B ROC curves with AUC values for the same assay using 100 μl or 250 μl sample volumes illustrate the diagnostic accuracy of both volumes. The plots show the median, 25th–75th percentiles (box), and whiskers extending to 1.5 × IQR, with individual data points overlaid. C The correlation between the PAβ V1.0 and PAβ V2.0 assays was assessed for both 100 μl and 250 μl volumes, with Aβ1-40 and Aβ1-42 normalized using their respective ISs and other peptides normalized using Aβ1-38 IS. Spearman correlation was used to evaluate the strength of the relationships.

Back to article page